Medical Devices industry cross border deals total $6.67bn globally in Q1 2021

Boston Scientific ’s $1.07bn asset transaction deal with Lumenis was the medical devices industry’s biggest cross border deal of Q1 2021 as cross border deals worth $6.67bn were announced globally in the quarter, according to GlobalData’s deals database.

The value marked a decrease of 5.5% over the previous quarter and a drop of 16.4% when compared with the last four-quarter average of $7.98bn.

In terms of number of cross border deals, the sector saw a rise of 17.14% with 135 deals in Q1 2021 against the average of 115.25 deals in the last four-quarters.

In value terms, North America led the activity with cross border deals worth $2.73bn.

medical devices industry cross border deals in Q1 2021: Top deals

The top five medical devices industry cross border deals accounted for 53.8% of the overall value during Q1 2021.

The combined value of the top five cross border deals stood at $3.59bn, against the overall value of $6.67bn recorded for the quarter.

The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:

1) Boston Scientific’s $1.07bn asset transaction deal with Lumenis

2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific

3) Koninklijke Philips’ $635m acquisition of Capsule Technologies

4) The $591m acquisition of Oxford Immunotec by PerkinElmer

5) Savaria ’s acquisition of Handicare Group for $409.7m.